Stock NUS NU SKIN ENTERPRISES, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Ratings Nu Skin Enterprises, Inc. Börse Stuttgart

Equities

NUS

US67018T1051

Market Closed - Börse Stuttgart
Other stock markets
 02:03:14 2024-07-02 EDT 		5-day change 1st Jan Change
9.6 EUR +0.52% Intraday chart for Nu Skin Enterprises, Inc. -17.67% -45.11%
05-09 DA Davidson Adjusts Nu Skin Enterprises' Price Target to $12.50 From $15.50, Keeps Neutral Rating MT
05-08 Transcript : Nu Skin Enterprises, Inc., Q1 2024 Earnings Call, May 08, 2024

Summary

  • Overall, and from a short-term perspective, the company presents an interesting fundamental situation.

Strengths

  • The company's earnings per share (EPS) are expected to grow significantly over the next few years according to the consensus of analysts covering the stock.
  • The company's attractive earnings multiples are brought to light by a P/E ratio at 11.76 for the current year.
  • The company shows low valuation levels, with an enterprise value at 0.41 times its sales.
  • Given the positive cash flows generated by its business, the company's valuation level is an asset.
  • The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
  • The divergence of price targets given by the various analysts who make up the consensus is relatively low, suggesting a consensus method of evaluating the company and its prospects.

Weaknesses

  • As estimated by analysts, this group is among those businesses with the lowest growth prospects.
  • The company's profitability before interest, taxes, depreciation and amortization characterizes fragile margins.
  • The company does not generate enough profits, which is an alarming weak point.
  • For the last twelve months, sales expectations have been significantly downgraded, which means that less important sales volumes are expected for the current fiscal year over the previous period.
  • For the last four months, the sales outlook for the coming years has been revised downwards. No recovery of the group's activities is yet foreseen.
  • For the past year, analysts have significantly revised downwards their profit estimates.
  • For the last four months, EPS estimates made by Standard & Poor's analysts have been revised downwards.
  • Over the past four months, analysts' average price target has been revised downwards significantly.

Ratings chart - Surperformance

Sector: Personal Products

1st Jan change Capi. Investor Rating ESG Refinitiv
NU SKIN ENTERPRISES, INC. Stock Nu Skin Enterprises, Inc.
-45.11% 517M -
PROCTER & GAMBLE COMPANY Stock Procter & Gamble Company
+11.85% 384B
C-
UNILEVER PLC Stock Unilever PLC
+13.37% 137B
B-
COLGATE-PALMOLIVE COMPANY Stock Colgate-Palmolive Company
+20.59% 78.38B
A+
HINDUSTAN UNILEVER LIMITED Stock Hindustan Unilever Limited
-6.69% 70.44B
A-
ESTEE LAUDER Stock Estee Lauder
-27.61% 37.79B
B+
KENVUE INC. Stock Kenvue Inc.
-15.28% 34.37B -
BEIERSDORF Stock Beiersdorf
+0.66% 32.77B
B-
ESSITY AB Stock Essity AB
+9.64% 18.2B
A-
GODREJ CONSUMER PRODUCTS LIMITED Stock Godrej Consumer Products Limited
+21.21% 17.13B
B
Investor Rating
Trading Rating
ESG Refinitiv
-

Financials

Sales growth
Earnings Growth
EBITDA / Sales
Profitability
Finances

Valuation

P/E ratio
EV / Sales
Price to Book
-
Price to Free Cash Flow
Yield

Momentum

1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision

Consensus

Analyst Opinion
Potential Price Target
4m Target Price Revision
4m Revision of opinion
-
12m Revision of opinion
-

Business Predictability

Analyst Coverage
Divergence of Estimates
Divergence of analysts' opinions
Divergence of Target Price
Earnings quality

Technical analysis

ST Timing
MT Timing
LT Timing
RSI
Bollinger Spread
Unusual volumes
  1. Stock Market
  2. Equities
  3. NUS Stock
  4. NUS Stock
  5. Ratings Nu Skin Enterprises, Inc.